5-(but-3-yn-2-yl)-1,2,3-trimethoxybenzene | 931103-03-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-(but-3-yn-2-yl)-1,2,3-trimethoxybenzene
• 英文别名: 5-but-3-yn-2-yl-1,2,3-trimethoxybenzene
• CAS: 931103-03-6
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: NVGOXTCHTQBLHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(but-3-yn-2-yl)-1,2,3-trimethoxybenzene 在 2-溴吡啶-1-氧化物 、 甲烷磺酸 、 Bis(2,4-ditert-butylphenoxy)-[2-(2,4,6-trimethoxyphenyl)phenyl]phosphane;bis(trifluoromethylsulfonyl)azanide;gold(1+) 作用下， 以 氯仿 为溶剂， 反应 0.5h， 以68%的产率得到4,5,6-trimethoxy-1-methyl-1H-inden-2(3H)-one
  参考文献：
  名称：

  联芳基亚膦酸酯金（I）配合物是将炔丙基芳烃氧化环化为Indan-2-one的高级催化剂

  摘要：

  打击金：通过新的金（I）催化的氧化环化工艺，一系列功能化的丙炔基芳烃被顺利转化为茚满-2-酮。就本转化而言，就收率和动力学而言，[ L Au] NTf 2（Tf ＝三氟甲磺酰基）是优良的催化剂。

  DOI：

  10.1002/anie.201301015
• 作为产物：
  描述：

  2-(3,4,5-三甲氧基苯基)丙醛 在 叔丁基锂 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 5-(but-3-yn-2-yl)-1,2,3-trimethoxybenzene
  参考文献：
  名称：

  联芳基亚膦酸酯金（I）配合物是将炔丙基芳烃氧化环化为Indan-2-one的高级催化剂

  摘要：

  打击金：通过新的金（I）催化的氧化环化工艺，一系列功能化的丙炔基芳烃被顺利转化为茚满-2-酮。就本转化而言，就收率和动力学而言，[ L Au] NTf 2（Tf ＝三氟甲磺酰基）是优良的催化剂。

  DOI：

  10.1002/anie.201301015

文献信息

• Inhibitors of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal and Anticancer Properties
  申请人：Anderson Amy C.

  公开号：US20090105287A1

  公开（公告）日：2009-04-23

  The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus , fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii . These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

  本文描述的组合物和方法揭示了设计、合成和测试作为DHFR抑制剂的化合物。这些抑制剂的基本骨架包括一个2,4-二氨基嘧啶环，带有一个丙炔基连接到另一个取代芳基、双环或杂环芳基环。这些DHFR抑制剂对许多不同的病原体具有强大的选择性作用，包括来自细菌如炭疽芽胞杆菌和耐甲氧西林金黄色葡萄球菌、真菌如白色假丝酵母、白念珠菌和新生隐球菌，以及原虫如人类隐孢子虫和弓形虫的DHFR酶。这些化合物和其他类似化合物也对哺乳动物酶具有强大的作用，可能有助于作为抗癌治疗药物。
• HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE
  申请人：Anderson Amy C.

  公开号：US20120196859A1

  公开（公告）日：2012-08-02

  The compositions and methods described herein disclose the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus , fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii . These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

  本文所描述的组合物和方法揭示了设计、合成和测试作为DHFR抑制剂的化合物。这些抑制剂的基本骨架包括一个2,4-二氨基嘧啶环，带有一个丙炔基连接到另一个取代芳基、双环或杂环环上。这些DHFR抑制剂对许多不同的病原微生物具有强效和选择性作用，包括来自细菌（如炭疽芽孢杆菌和甲氧西林耐药金黄色葡萄球菌）、真菌（如光滑念珠菌、白色念珠菌和新生隐球菌）和原虫（如人类隐孢子虫和弓形虫）的DHFR酶。这些化合物和其他类似化合物也对哺乳动物酶具有强效作用，可能有用作抗癌治疗药物。
• Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
  申请人：Anderson Amy C.

  公开号：US08853228B2

  公开（公告）日：2014-10-07

  The compositions and methods described herein disclose the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

  本文所述的组合物和方法揭示了设计、合成和测试作为DHFR抑制剂的化合物。这些抑制剂的基本支架包括一个2,4-二氨基嘧啶环，带有一个丙炔基连接到另一个取代芳基、双环或杂环环上。这些DHFR抑制剂对许多不同的致病微生物具有强效和选择性，包括来自细菌如炭疽芽孢杆菌和耐甲氧西林金黄色葡萄球菌的DHFR酶，真菌如光滑念珠菌，白色念珠菌和新型隐球菌和原虫如人类隐孢子虫和弓形虫的DHFR酶。这些化合物和其他类似化合物也对哺乳动物酶具有强效作用，可能有用作抗癌治疗药物。
• Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties
  申请人：Anderson Amy C.

  公开号：US08426432B2

  公开（公告）日：2013-04-23

  The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

  本文所述的组分和方法揭示了设计、合成和测试作为DHFR抑制剂的化合物。这些抑制剂的基本骨架包括一个2,4-二氨基嘧啶环，带有一个丙炔基连接到另一个取代芳基、双环或杂环环。这些DHFR抑制剂对许多不同的致病微生物具有强效和选择性，包括来自细菌（如炭疽芽孢杆菌和耐甲氧西林金黄色葡萄球菌的DHFR酶）、真菌（如光滑念珠菌、白色念珠菌和新型隐球菌）和原虫（如人类隐孢子虫和弓形虫的隐孢子虫）。这些化合物和其他类似化合物对哺乳动物酶也具有强效作用，并可能用作抗癌治疗药物。
• Highly Efficient Ligands for Dihydrofolate Reductase from <i>Cryptosporidium </i><i>hominis</i> and <i>Toxoplasma </i><i>gondii</i> Inspired by Structural Analysis
  作者：Phillip M. Pelphrey、Veljko M. Popov、Tammy M. Joska、Jennifer M. Beierlein、Erin S. D. Bolstad、Yale A. Fillingham、Dennis L. Wright、Amy C. Anderson

  DOI：10.1021/jm061027h

  日期：2007.3.1

  The search for effective therapeutics for cryptosporidiosis and toxoplasmosis has led to the discovery of novel inhibitors of dihydrofolate reductase (DHFR) that possess high ligand efficiency: compounds with high potency and low molecular weight. Detailed analysis of the crystal structure of dihydrofolate reductase-thymidylate synthase from Cryptosporidium hominis and a homology model of DHFR from Toxoplasma gondii inspired the synthesis of a new series of compounds with a propargyl-based linker between a substituted 2,4-diaminopyrimidine and a trimethoxyphenyl ring. An enantiomerically pure compound in this series exhibits IC50 values of 38 and 1 nM against C. hominis and T. gondii DHFR, respectively. Improvements of 368-fold or 5714-fold (C. hominis and T. gondii) relative to trimethoprim were generated by synthesizing just 14 new analogues and by adding only a total of 52 Da to the mass of the parent compound, creating an efficient ligand as an excellent candidate for further study.